AAAAAA

   
Results: 1-25 | 26-50 | 51-72
Results: 1-25/72
MITOXANTRONE VERSUS DAUNORUBICIN IN INDUCTION-CONSOLIDATION CHEMOTHERAPY - THE VALUE OF LOW-DOSE CYTARABINE FOR MAINTENANCE OF REMISSION, AND AN ASSESSMENT OF PROGNOSTIC FACTORS IN ACUTE MYELOID-LEUKEMIA IN THE ELDERLY - FINAL REPORT OF THE LEUKEMIA COOPERATIVE GROUP OF THE ANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER AND THE DUTCH-BELGIAN HEMATOONCOLOGY COOPERATIVE HOVON GROUP RANDOMIZED PHASE-III STUDY AML-9
Authors: LOWENBERG B SUCIU S ARCHIMBAUD E HAAK H STRYCKMANS P DECATALDO R DEKKER AW BERNEMAN ZN THYSS A VANDERLELIE J SONNEVELD P VISANI G FILLET G HAYAT M HAGEMEIJER A SOLBU G ZITTOUN R
Citation: B. Lowenberg et al., MITOXANTRONE VERSUS DAUNORUBICIN IN INDUCTION-CONSOLIDATION CHEMOTHERAPY - THE VALUE OF LOW-DOSE CYTARABINE FOR MAINTENANCE OF REMISSION, AND AN ASSESSMENT OF PROGNOSTIC FACTORS IN ACUTE MYELOID-LEUKEMIA IN THE ELDERLY - FINAL REPORT OF THE LEUKEMIA COOPERATIVE GROUP OF THE ANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER AND THE DUTCH-BELGIAN HEMATOONCOLOGY COOPERATIVE HOVON GROUP RANDOMIZED PHASE-III STUDY AML-9, Journal of clinical oncology, 16(3), 1998, pp. 872-881
TIME TO RELAPSE HAS PROGNOSTIC VALUE IN PATIENTS WITH AGGRESSIVE LYMPHOMA ENROLLED ONTO THE PARMA TRIAL
Authors: GUGLIELMI C GOMEZ F PHILIP T HAGENBEEK A MARTELLI M SEBBAN C MILPIED N BRON D CAHN JY SOMERS R SONNEVELD P GISSELBRECHT C VANDERLELIE H CHAUVIN F
Citation: C. Guglielmi et al., TIME TO RELAPSE HAS PROGNOSTIC VALUE IN PATIENTS WITH AGGRESSIVE LYMPHOMA ENROLLED ONTO THE PARMA TRIAL, Journal of clinical oncology, 16(10), 1998, pp. 3264-3269
COLOR-FLOW IMAGING SONOGRAPHY OF PORTAL AND HEPATIC VEIN FLOW TO MONITOR FIBRINOLYTIC THERAPY WITH R-TPA FOR VENOOCCLUSIVE DISEASE FOLLOWING MYELOABLATIVE TREATMENT
Authors: SONNEVELD P LAMERIS JS CORNELISSEN J OGILVIE A LOWENBERG B
Citation: P. Sonneveld et al., COLOR-FLOW IMAGING SONOGRAPHY OF PORTAL AND HEPATIC VEIN FLOW TO MONITOR FIBRINOLYTIC THERAPY WITH R-TPA FOR VENOOCCLUSIVE DISEASE FOLLOWING MYELOABLATIVE TREATMENT, Bone marrow transplantation, 21(7), 1998, pp. 731-734
LONG-TERM OUTCOME OF RELAPSED NON-HODGKINS-LYMPHOMA (NHL) PATIENTS INCLUDED IN THE PARMA TRIAL - INCIDENCE OF LATE RELAPSES, LONG-TERM TOXICITY AND IMPACT OF THE INTERNATIONAL PROGNOSTIC INDEX (IPI) AT RELAPSE
Authors: PHILIP T GOMEZ F GUGLIELMI C HAGENBEEK A SEBBAN C MILPIED N BRON D CAHN JY SOMERS R SONNEVELD P GISSELBRECHT C VANDERLELIE H CHAUVIN F
Citation: T. Philip et al., LONG-TERM OUTCOME OF RELAPSED NON-HODGKINS-LYMPHOMA (NHL) PATIENTS INCLUDED IN THE PARMA TRIAL - INCIDENCE OF LATE RELAPSES, LONG-TERM TOXICITY AND IMPACT OF THE INTERNATIONAL PROGNOSTIC INDEX (IPI) AT RELAPSE, Bone marrow transplantation, 21, 1998, pp. 595-595
TIME TO RELAPSE HAS PROGNOSTIC VALUE IN AGGRESSIVE LYMPHOMA ENROLLED IN THE PARMA TRIAL AT FIRST RELAPSE
Authors: GUGLIELMI C GOMEZ F HAGENBEEK A SEBBAN C MARTELLI M MILPIED N BRON D CAHN JY SOMERS R SONNEVELD P GISSELBRECHT C VANDERLELIE H CHAUVIN F PHILIP T
Citation: C. Guglielmi et al., TIME TO RELAPSE HAS PROGNOSTIC VALUE IN AGGRESSIVE LYMPHOMA ENROLLED IN THE PARMA TRIAL AT FIRST RELAPSE, Bone marrow transplantation, 21, 1998, pp. 623-623
VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) INDUCTION THERAPY FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY
Authors: LOKHORST HM SONNEVELD P CORNELISSEN JJ CROOCKEWIT S VANDERHOLT B KOOY MV VANOERS RHJ RICHEL D SEGEREN C VELLENGA E VERDONCK LF VERHOEF G WIJERMANS PW
Citation: Hm. Lokhorst et al., VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) INDUCTION THERAPY FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY, Bone marrow transplantation, 21, 1998, pp. 709-709
BUDD-CHIARI-SYNDROME, PORTAL-VEIN AND MESENTERIC VEIN-THROMBOSIS IN APATIENT HOMOZYGOUS FOR FACTOR-V-LEIDEN MUTATION TREATED BY TIPS AND THROMBOLYSIS
Authors: LEEBEEK FWG LAMERIS JS VANBUUREN HR GOMEZ E MADRETSMA S SONNEVELD P
Citation: Fwg. Leebeek et al., BUDD-CHIARI-SYNDROME, PORTAL-VEIN AND MESENTERIC VEIN-THROMBOSIS IN APATIENT HOMOZYGOUS FOR FACTOR-V-LEIDEN MUTATION TREATED BY TIPS AND THROMBOLYSIS, British Journal of Haematology, 102(4), 1998, pp. 929-931
VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY
Authors: LOKHORST HM SONNEVELD P CORNELISSEN JJ CROOCKEWIT S VANDERHOLT B KOOY MV VANOERS RHJ RICHEL D SEGEREN C VELLENGA E VERDONCK LF VERHOEF G WIJERMANS PW
Citation: Hm. Lokhorst et al., VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY, British Journal of Haematology, 102(1), 1998, pp. 6-7
EFFICACY OF STANDARD CHOP CHEMOTHERAPY IN ELDERLY PATIENTS WITH POOR-RISK NON-HODGKINS-LYMPHOMA (NHL)
Authors: DOORDUIJN JK VANDERHOLT B BREED WPM VANDERHEM KG VANIMHOFF GW KRAMER MHH KOOY MV VANOERS MHJ OSSENKOPPELE GJ RICHEL DJ ROOZENDAAL KJ VANTVEER MB VERDONCK LF VERHOEF G WIJERMANS PW SONNEVELD P
Citation: Jk. Doorduijn et al., EFFICACY OF STANDARD CHOP CHEMOTHERAPY IN ELDERLY PATIENTS WITH POOR-RISK NON-HODGKINS-LYMPHOMA (NHL), British Journal of Haematology, 102(1), 1998, pp. 149-149
FAVORABLE LONG-TERM RESULTS OF A 2-HOURS INFUSION REGIMEN OF 2-CHLORODEOXYADENOSINE IN HAIRY-CELL LEUKEMIA
Authors: RAEMAEKERS J VANTVEER M VERHOEF G HUIJGENS PC SONNEVELD P DEBOCK B
Citation: J. Raemaekers et al., FAVORABLE LONG-TERM RESULTS OF A 2-HOURS INFUSION REGIMEN OF 2-CHLORODEOXYADENOSINE IN HAIRY-CELL LEUKEMIA, British Journal of Haematology, 102(1), 1998, pp. 189-189
MEASUREMENT OF MESSENGER-RNA AND PROTEIN-LEVELS OF MRP1 AND LRP IN ELDERLY DE-NOVO ACUTE MYELOID-LEUKEMIA
Authors: VOSSEBELD PJM WIEMER EAC SONNEVELD P
Citation: Pjm. Vossebeld et al., MEASUREMENT OF MESSENGER-RNA AND PROTEIN-LEVELS OF MRP1 AND LRP IN ELDERLY DE-NOVO ACUTE MYELOID-LEUKEMIA, British Journal of Haematology, 102(1), 1998, pp. 332-332
INTRACELLULAR-LOCALIZATION OF THE VAULT COMPLEX IN NON-P-GP MULTIDRUG-RESISTANT CELL-LINES
Authors: WIEMER EAC VOSSEBELD PJM SONNEVELD P
Citation: Eac. Wiemer et al., INTRACELLULAR-LOCALIZATION OF THE VAULT COMPLEX IN NON-P-GP MULTIDRUG-RESISTANT CELL-LINES, British Journal of Haematology, 102(1), 1998, pp. 332-333
LUNG-RESISTANCE-RELATED PROTEIN EXPRESSION IS A NEGATIVE PREDICTIVE FACTOR FOR RESPONSE TO CONVENTIONAL LOW BUT NOT TO INTENSIFIED DOSE ALKYLATING CHEMOTHERAPY IN MULTIPLE-MYELOMA
Authors: RAAIJMAKERS HGP IZQUIERDO MAI LOKHORST HM DELEEUW C BELIEN JAM BLOEM AC DEKKER AW SCHEPER RJ SONNEVELD P
Citation: Hgp. Raaijmakers et al., LUNG-RESISTANCE-RELATED PROTEIN EXPRESSION IS A NEGATIVE PREDICTIVE FACTOR FOR RESPONSE TO CONVENTIONAL LOW BUT NOT TO INTENSIFIED DOSE ALKYLATING CHEMOTHERAPY IN MULTIPLE-MYELOMA, Blood, 91(3), 1998, pp. 1029-1036
PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SDZ PSC-833, A NOVEL MULTIDRUG-RESISTANCE REVERSING AGENT, IN PHASE-1 TRIALS WITH CHEMOTHERAPEUTIC-AGENTS
Authors: CHARNICK SB FRACASSO P EGORIN M SONNEVELD P BLEEHAN N GIACCONE G NIEDERBERGER W SMITH HT PEARCE T SIKIC BI
Citation: Sb. Charnick et al., PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF SDZ PSC-833, A NOVEL MULTIDRUG-RESISTANCE REVERSING AGENT, IN PHASE-1 TRIALS WITH CHEMOTHERAPEUTIC-AGENTS, European journal of cancer, 33, 1997, pp. 775-775
ASSAYS FOR THE ANALYSIS OF P-GLYCOPROTEIN IN ACUTE MYELOID-LEUKEMIA AND CD34 SUBSETS OF AML BLASTS
Authors: SONNEVELD P WIEMER E
Citation: P. Sonneveld et E. Wiemer, ASSAYS FOR THE ANALYSIS OF P-GLYCOPROTEIN IN ACUTE MYELOID-LEUKEMIA AND CD34 SUBSETS OF AML BLASTS, Leukemia, 11(7), 1997, pp. 1160-1165
INTENSIVE POSTREMISSION CHEMOTHERAPY WITHOUT MAINTENANCE THERAPY IN ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: DEKKER AW VANTVEER MB SIZOO W HAAK HL VANDERLELIE J OSSENKOPPELE G HUIJGENS PC SCHOUTEN HC SONNEVELD P WILLEMZE R VERDONCK LF VANPUTTEN WLJ LOWENBERG B
Citation: Aw. Dekker et al., INTENSIVE POSTREMISSION CHEMOTHERAPY WITHOUT MAINTENANCE THERAPY IN ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA, Journal of clinical oncology, 15(2), 1997, pp. 476-482
DRUG-RESISTANCE IN MULTIPLE-MYELOMA
Authors: SONNEVELD P LOKHORST HM VOSSEBELD P
Citation: P. Sonneveld et al., DRUG-RESISTANCE IN MULTIPLE-MYELOMA, Seminars in hematology, 34(4), 1997, pp. 34-39
MDR-1 EXPRESSION IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RESPONSE ANDSURVIVAL IN DE-NOVO ACUTE MYELOID-LEUKEMIA
Authors: VANDENHEUVELEIBRINK MM VANDERHOLT B TEBOEKHORST PAW PIETERS R SCHOESTER M LOWENBERG B SONNEVELD P
Citation: Mm. Vandenheuveleibrink et al., MDR-1 EXPRESSION IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RESPONSE ANDSURVIVAL IN DE-NOVO ACUTE MYELOID-LEUKEMIA, British Journal of Haematology, 99(1), 1997, pp. 76-83
USE OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR DURING AND AFTER REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS AGED 61 YEARS AND OLDER WITH ACUTE MYELOID-LEUKEMIA (AML) - FINAL REPORT OF AML-11, A PHASE-III RANDOMIZED STUDY OF THE LEUKEMIA COOPERATIVE GROUP OFANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC-LCG) AND THE DUTCH BELGIAN HEMATOONCOLOGY COOPERATIVE GROUP (HOVON)
Authors: LOWENBERG B SUCIU S ARCHIMBAUD E OSSENKOPPELE G VERHOEF GEG VELLENGA E WIJERMANS P BERNEMAN Z DEKKER AW STRYCKMANS P SCHOUTEN H JEHN U MUUS P SONNEVELD P DARDENNE M ZITTOUN R
Citation: B. Lowenberg et al., USE OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR DURING AND AFTER REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS AGED 61 YEARS AND OLDER WITH ACUTE MYELOID-LEUKEMIA (AML) - FINAL REPORT OF AML-11, A PHASE-III RANDOMIZED STUDY OF THE LEUKEMIA COOPERATIVE GROUP OFANIZATION-FOR-THE-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC-LCG) AND THE DUTCH BELGIAN HEMATOONCOLOGY COOPERATIVE GROUP (HOVON), Blood, 90(8), 1997, pp. 2952-2961
CYCLOSPORINE-A COMBINED WITH VAD VS VAD IN PATIENTS WITH REFRACTORY MULTIPLE-MYELOMA - AN EORTC HOVON RANDOMIZED PHASE-II STUDY/
Authors: SONNEVELD P SUCIU S WEIJERMANS P BEKSAC M NEUWIRTOVA R SOLBU G LOKHORST H VANDERLELIE J DOHNER H GERHARTZ H SEGEREN CM WILLEMZE R LOWENBERG B
Citation: P. Sonneveld et al., CYCLOSPORINE-A COMBINED WITH VAD VS VAD IN PATIENTS WITH REFRACTORY MULTIPLE-MYELOMA - AN EORTC HOVON RANDOMIZED PHASE-II STUDY/, Blood, 90(10), 1997, pp. 1590-1590
VAD ADMINISTERED AS INTRAVENOUS PUSH INJECTION AS FIRST-LINE TREATMENT IN STAGE II III MULTIPLE-MYELOMA/
Authors: SEGEREN CM VANDERHOLT B SONNEVELD P CROOCKEWIT S VELLENGA E VANOERS MHJ RICHEL D VERHOEF G CORNELISSEN JJ LOKHORST HM
Citation: Cm. Segeren et al., VAD ADMINISTERED AS INTRAVENOUS PUSH INJECTION AS FIRST-LINE TREATMENT IN STAGE II III MULTIPLE-MYELOMA/, Blood, 90(10), 1997, pp. 1591-1591
DOSE-FINDING STUDY OF PSC833, A NOVEL MDR REVERSING AGENT, WITH DAUNORUBICIN AND ARA-C IN UNTREATED ELDERLY PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML)
Authors: SONNEVELD P LOWENBERG B VOSSEBELD P MALKHANDI J COVELLI A DEKKER AW OSSENKOPPELE G MILLIGAN D VERHOEF G FERRANT A YIN J GRATWOHL A KOVACSOVICS T BURNETT A
Citation: P. Sonneveld et al., DOSE-FINDING STUDY OF PSC833, A NOVEL MDR REVERSING AGENT, WITH DAUNORUBICIN AND ARA-C IN UNTREATED ELDERLY PATIENTS WITH ACUTE MYELOID-LEUKEMIA (AML), Blood, 90(10), 1997, pp. 2517-2517
REVERSAL OF MULTIDRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA AND OTHER HEMATOLOGICAL MALIGNANCIES
Authors: SONNEVELD P
Citation: P. Sonneveld, REVERSAL OF MULTIDRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA AND OTHER HEMATOLOGICAL MALIGNANCIES, European journal of cancer, 32A(6), 1996, pp. 1062-1069
MULTIDRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA
Authors: SONNEVELD P
Citation: P. Sonneveld, MULTIDRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA, Bailliere's clinical haematology, 9(1), 1996, pp. 185-203
IN-VITRO EFFECT OF GF120918, A NOVEL REVERSAL AGENT OF MULTIDRUG-RESISTANCE, ON ACUTE-LEUKEMIA AND MULTIPLE-MYELOMA CELLS
Authors: DENOUDEN D VANDENHEUVEL M SCHOESTER M VANRENS G SONNEVELD P
Citation: D. Denouden et al., IN-VITRO EFFECT OF GF120918, A NOVEL REVERSAL AGENT OF MULTIDRUG-RESISTANCE, ON ACUTE-LEUKEMIA AND MULTIPLE-MYELOMA CELLS, Leukemia, 10(12), 1996, pp. 1930-1936
Risultati: 1-25 | 26-50 | 51-72